Surgical Science Sweden AB (publ) (SUS)
Free
No email, no account, no signup.
Pulling latest news for Surgical Science Sweden AB (publ)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
HOLD
Sentiment
7/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has turned clearly positive after a well-received Q1, strong cash flow and CEO insider buying; discussions now emphasize undervaluation and the cash position more than near-term OEM/license uncertainty.
Exchange
Nasdaq First North Growth Market Stockholm
Sector
MedTech – VR surgical training simulators
Market Cap
$155M
Market sentiment
Sentiment has turned clearly positive after a well-received Q1, strong cash flow and CEO insider buying; discussions now emphasize undervaluation and the cash position more than near-term OEM/license uncertainty.
Why HOLD ?
- **Hold** given the strong balance sheet and structural market growth.
- However, **2026 revenue/margin visibility is weak** due to the Intuitive impact.
- Wait for **evidence in upcoming reports** that Educational Products and cost actions can offset the gap.
- Wait for the Q1 report; consider a small add (up to ~10%) only after confirmed stabilization in license revenue/margins.
Recent News
- Since the last analysis (2026-05-22), no new press releases or company-specific events have been published. The latest known items remain the Q1 2026 report (May 20) with revenue of SEK 235.5m, strong operating cash flow of +SEK 65.3m and cash of SEK 667.7m, and the AGM (May 21) authorising up to 10% share issuance and a new incentive program. The next key data point is the Q2 report on 19 August 2026.
Bull case
- **Oversold share price** after a steep decline may trigger a technical rebound.
- **Strong net cash** provides downside support and flexibility.
Unlock to read more →
Bear case
- **License revenue may drop** as the Intuitive impact starts to show.
Unlock to read more →
Catalysts
19 Aug 2026 — Uplisting to Nasdaq Main Market
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Surgical Science Sweden AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.